Tag: biosimilar vs reference product

Adverse Event Monitoring for Biosimilars: How Safety Surveillance Works Today
Jan 18 2026 Hudson Bellamy

Adverse Event Monitoring for Biosimilars: How Safety Surveillance Works Today

Biosimilars require specialized safety monitoring because they're not identical to reference biologics. Learn how adverse event reporting, traceability, and active surveillance systems ensure patient safety while supporting cost-effective treatment options.

Detail